Palisade Bio, Inc. Common Stock (PALI) Stock Price

PALIStock

$2.00+194.12%52W

Market Cap$348.54M

P/E—

PEG Ratio—

Div yield—

Beta1.52

PALI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-0.20%

Price vs S&P 500 (4W)1.55%

VGM Score43.57

Book Value / Share (Quarterly)$0.76

P/TBV (Annual)1.58x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-27.71%

Net Profit Margin (TTM)-936.00%

EPS (TTM)$-1.17

10-Day Avg Trading Volume1.63M

EPS Excl Extra (TTM)$-1.17

EPS (Annual)$-10.19

ROI (Annual)-190.70%

Net Profit Margin (5Y Avg)-37513.22%

Cash / Share (Quarterly)$0.79

ROA (Last FY)-132.70%

EBITD / Share (TTM)$-0.38

ROE (5Y Avg)-188.72%

Operating Margin (TTM)-1011.60%

Cash Flow / Share (Annual)$-0.07

P/B Ratio2.89x

P/B Ratio (Quarterly)2.30x

Net Income / Employee (Annual)$-1,031,300

EV / Revenue (TTM)943.82x

Net Interest Coverage (TTM)-1202.17x

ROA (TTM)-34.34%

EPS Incl Extra (Annual)$-10.19

Current Ratio (Annual)28.95x

Quick Ratio (Quarterly)23.60x

3-Month Avg Trading Volume3.07M

52-Week Price Return194.12%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1896.75

P/S Ratio (Annual)1474.33x

Asset Turnover (Annual)0.02x

52-Week High$2.85

Operating Margin (5Y Avg)-29730.27%

EPS Excl Extra (Annual)$-10.19

Tangible BV CAGR (5Y)20.01%

26-Week Price Return11.73%

Quick Ratio (Annual)28.83x

13-Week Price Return-2.91%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)23.71x

Enterprise Value$235.95M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-79.85%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-4920.00%

Cash / Share (Annual)$0.84

3-Month Return Std Dev77.31%

Net Income / Employee (TTM)$-1,725,100

ROE (Last FY)-192.71%

Net Interest Coverage (Annual)-2414.10x

EPS Basic Excl Extra (Annual)$-10.19

Receivables Turnover (TTM)0.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.17

Receivables Turnover (Annual)0.20x

ROI (TTM)-36.71%

P/S Ratio (TTM)1474.33x

Pretax Margin (5Y Avg)-37513.22%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2405.25

Price vs S&P 500 (52W)175.56%

Year-to-Date Return-14.89%

5-Day Price Return-0.50%

EPS Normalized (Annual)$-10.19

ROA (5Y Avg)-129.62%

Net Profit Margin (Annual)-4920.00%

Month-to-Date Return5.54%

Cash Flow / Share (TTM)$-2.62

EBITD / Share (Annual)$-10.49

Operating Margin (Annual)-5228.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-187.02%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.17

P/TBV (Quarterly)3.88x

P/B Ratio (Annual)2.71x

Pretax Margin (TTM)-936.00%

Book Value / Share (Annual)$0.81

Price vs S&P 500 (13W)-4.87%

Beta1.52x

Revenue / Share (TTM)$0.00

ROE (TTM)-36.79%

52-Week Low$0.53

vGradeD

mGradeB

vgmGradeC

PALI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.05	-$0.05	+5.41%(+$0.00)
Q3 2025	Nov 10, 2025	-$0.27	-$0.38	-39.03%(-$0.11)
Q2 2025	Aug 11, 2025	-$0.56	-$0.58	-3.57%(-$0.02)

PALI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

4.27

4.31

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
PALIPalisade Bio, Inc. Common Stock	D	—	B	$2.00
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Palisade Bio, Inc. Common Stock

Palisade Bio is a clinical-stage biopharmaceutical company developing therapeutics to protect intestinal barrier function. Its lead candidate, PALI-2108, targets inflammatory bowel disease, including ulcerative colitis and Crohn's disease, while PALI-1908 is in early-stage research. The company is positioned in the gastrointestinal immunology market.